Nebenwirkungen · Erelzi
Erelzi 25 mg solution for injection in pre-filled syringe Erelzi 50 mg solution for injection in pre-filled syringe Erelzi 50 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 14–15
HOS-224846 · Präparat HOS-217364
Serious and fatal infections have been reported during use of etanercept; reported pathogens include bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few weeks after initiating treatment with etanercept in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid 14 arthritis (see section 4.4). Etanercept treatment may increase mortality in patients with established sepsis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:32:00Z · SHA-256 8d6ebe8e6bd3cb1e5cf00387c96a1b26847dafa37c621335614a04ecbffe7cc5 · Passage d7b82d09289688f68048ca9665cf9386c3b55b150fa32af5f086c5fc7e981e88 · Zeichen 16672–17247 im Abschnitt